vs
Granite Point Mortgage Trust Inc.（GPMT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Granite Point Mortgage Trust Inc.的1.0倍（$30.3M vs $29.1M），Granite Point Mortgage Trust Inc.净利率更高（-81.9% vs -221.3%，领先139.4%），REGENXBIO Inc.同比增速更快（43.0% vs -24.9%），过去两年Granite Point Mortgage Trust Inc.的营收复合增速更高（52.3% vs 39.4%）
Granite Point Mortgage Trust Inc.是一家总部位于美国的房地产金融企业，主要从事优先担保商业房地产贷款的发放、管理与投资业务，资产组合覆盖多户型住宅、办公楼、工业及零售物业等类别，业务遍及美国核心区域市场。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GPMT vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$29.1M
营收增速更快
RGNX
高出67.9%
-24.9%
净利率更高
GPMT
高出139.4%
-221.3%
两年增速更快
GPMT
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.1M | $30.3M |
| 净利润 | $-23.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -81.9% | -190.0% |
| 净利率 | -81.9% | -221.3% |
| 营收同比 | -24.9% | 43.0% |
| 净利润同比 | 38.7% | -31.2% |
| 每股收益（稀释后） | $-0.58 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GPMTRGNX
| Q4 25 | $29.1M | $30.3M | ||
| Q3 25 | $33.7M | $29.7M | ||
| Q2 25 | $33.8M | $21.4M | ||
| Q1 25 | $35.1M | $89.0M | ||
| Q4 24 | $38.7M | $21.2M | ||
| Q3 24 | $44.3M | $24.2M | ||
| Q2 24 | $48.5M | $22.3M | ||
| Q1 24 | $12.5M | $15.6M |
净利润GPMTRGNX
| Q4 25 | $-23.8M | $-67.1M | ||
| Q3 25 | $3.0M | $-61.9M | ||
| Q2 25 | $-13.4M | $-70.9M | ||
| Q1 25 | $-7.0M | $6.1M | ||
| Q4 24 | $-38.8M | $-51.2M | ||
| Q3 24 | $-31.0M | $-59.6M | ||
| Q2 24 | $-63.1M | $-53.0M | ||
| Q1 24 | $-74.1M | $-63.3M |
毛利率GPMTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率GPMTRGNX
| Q4 25 | -81.9% | -190.0% | ||
| Q3 25 | 9.2% | -176.3% | ||
| Q2 25 | -39.5% | -296.3% | ||
| Q1 25 | -19.8% | 13.6% | ||
| Q4 24 | -100.3% | -242.1% | ||
| Q3 24 | -70.0% | -256.6% | ||
| Q2 24 | -130.1% | -251.3% | ||
| Q1 24 | -591.9% | -408.8% |
净利率GPMTRGNX
| Q4 25 | -81.9% | -221.3% | ||
| Q3 25 | 9.0% | -208.3% | ||
| Q2 25 | -39.5% | -331.8% | ||
| Q1 25 | -20.0% | 6.8% | ||
| Q4 24 | -100.3% | -241.3% | ||
| Q3 24 | -70.0% | -246.3% | ||
| Q2 24 | -130.1% | -237.7% | ||
| Q1 24 | -591.9% | -405.4% |
每股收益（稀释后）GPMTRGNX
| Q4 25 | $-0.58 | $-1.30 | ||
| Q3 25 | $-0.01 | $-1.20 | ||
| Q2 25 | $-0.35 | $-1.38 | ||
| Q1 25 | $-0.22 | $0.12 | ||
| Q4 24 | $-0.86 | $-0.99 | ||
| Q3 24 | $-0.69 | $-1.17 | ||
| Q2 24 | $-1.31 | $-1.05 | ||
| Q1 24 | $-1.53 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $552.7M | $102.7M |
| 总资产 | $1.8B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GPMTRGNX
| Q4 25 | $66.0M | $230.1M | ||
| Q3 25 | $62.7M | $274.2M | ||
| Q2 25 | $85.1M | $323.3M | ||
| Q1 25 | $85.7M | $267.9M | ||
| Q4 24 | $87.8M | $234.7M | ||
| Q3 24 | $113.5M | $255.5M | ||
| Q2 24 | $85.9M | $290.4M | ||
| Q1 24 | $155.2M | $338.7M |
股东权益GPMTRGNX
| Q4 25 | $552.7M | $102.7M | ||
| Q3 25 | $582.0M | $161.5M | ||
| Q2 25 | $584.2M | $213.7M | ||
| Q1 25 | $604.7M | $274.2M | ||
| Q4 24 | $619.1M | $259.7M | ||
| Q3 24 | $667.8M | $301.4M | ||
| Q2 24 | $704.6M | $348.3M | ||
| Q1 24 | $774.1M | $390.7M |
总资产GPMTRGNX
| Q4 25 | $1.8B | $453.0M | ||
| Q3 25 | $1.8B | $525.2M | ||
| Q2 25 | $1.9B | $581.0M | ||
| Q1 25 | $2.0B | $490.9M | ||
| Q4 24 | $2.1B | $466.0M | ||
| Q3 24 | $2.3B | $519.1M | ||
| Q2 24 | $2.5B | $569.4M | ||
| Q1 24 | $2.7B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GPMTRGNX
| Q4 25 | $2.7M | $-52.3M | ||
| Q3 25 | $4.5M | $-56.0M | ||
| Q2 25 | $736.0K | $-49.3M | ||
| Q1 25 | $-5.7M | $33.6M | ||
| Q4 24 | $8.8M | $-31.6M | ||
| Q3 24 | $6.1M | $-40.5M | ||
| Q2 24 | $987.0K | $-45.5M | ||
| Q1 24 | $1.7M | $-55.5M |
自由现金流GPMTRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率GPMTRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度GPMTRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率GPMTRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GPMT
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
